Status In progress
Decision Selected
Process TA
ID number 1056

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Bayer
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups GIST Support Group
  Sarcoma UK
Professional groups Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
15 November 2017 Expected publication
12 October 2017 - 26 October 2017 Final appraisal determination
30 August 2017 Committee meeting: 2
02 August 2017 Following the recent discussion on 28 June, the committee concluded that it needed more information from the company before it can make a decision. Given the information is related to the technical aspects of the economic analysis, we will not be issuing any documentation at this stage. The committee will consider the additional information at its meeting on Wednesday 30 August 2017 and continue its deliberations on regorafenib for gastrointestinal stromal tumours.
28 June 2017 Committee meeting: 1
20 January 2017 Invitation to participate
20 September 2016 Draft scope documents
08 June 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual